Liquid biopsy in lung cancer

Area of Science:

• Oncology
• Molecular Diagnostics
• Genetics

Background:

• Precision medicine for non-small cell lung cancer (NSCLC) relies on biomarkers like genetic mutations and PD-L1 expression.
• Liquid biopsy, analyzing bodily fluids, is an emerging, minimally invasive alternative to traditional methods.
• It detects circulating tumor cells, circulating tumor DNA (ctDNA), and microRNA (miRNA) for cancer detection and monitoring.

Purpose of the Study:

• To evaluate the utility of liquid biopsy in non-small cell lung cancer (NSCLC) treatment.
• To highlight the advantages of liquid biopsy for early diagnosis, genotyping, and treatment monitoring.
• To discuss the role of ctDNA and miRNA in detecting molecular residual disease (MRD) and predicting recurrence.

Main Methods:

• Analysis of blood and other bodily fluids for cancer-related genetic abnormalities.
• Detection of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and microRNA (miRNA).
• Utilizing established tests like Cobas® EGFR Mutation Test v2 and Guardant360® CDx for mutation detection.

Main Results:

• Liquid biopsy provides crucial information for early cancer diagnosis, genotyping, and treatment monitoring.
• Elevated ctDNA and miRNA levels show promise for early diagnosis and detecting molecular residual disease (MRD).
• ctDNA analysis can detect MRD earlier than conventional imaging, aiding treatment adjustment and relapse detection.

Conclusions:

• Liquid biopsy is a valuable, minimally invasive tool complementing tissue biopsy in NSCLC.
• Its continuous development is essential for improving personalized lung cancer treatment strategies.
• Liquid biopsy offers significant potential for early detection, monitoring, and management of NSCLC.